Jamieson Wellness Earnings Call Signals Growth Momentum

Jamieson Wellness ((TSE:JWEL)) has held its Q4 earnings call. Read on for the main highlights of the call.

Jamieson Wellness’ latest earnings call struck an upbeat tone, as management leaned on double-digit top-line growth, expanding margins and a standout performance in China to frame a story of durable momentum. While higher SG&A, a drop in strategic partner revenue and a working-capital build weighed on reported results, executives argued that these investments are deliberate and manageable against strong underlying profitability.

Strong Consolidated and Branded Revenue Growth

Jamieson posted about 12% full-year consolidated revenue growth, with its core branded business advancing nearly 16%, underscoring the strength of its portfolio. In Q4, consolidated revenue rose 13.4% to $277.7 million, powered by Jamieson Brands’ 17.1% gain to $237.4 million and a 20.2% jump at Youtheory.

Geographic Diversification with China and International Outperformance

China remained the star, with full-year growth above 56% and Q4 up 43.9%, making the market a key growth engine. International revenue climbed 24% for the year and 39.2% in Q4, while Canada outpaced its home market with roughly 6% full-year growth and 5.5% growth in the quarter.

Gross Profit and Margin Expansion

Consolidated gross profit increased by $18.5 million in Q4 to $118.7 million, lifting consolidated gross margin by about 180 basis points and highlighting operating leverage. Jamieson Brands’ gross profit rose 19.7%, and normalized gross margin improved 90 basis points to 47.6%, helped by a richer branded mix and scale benefits in China.

Improved Profitability and Strong Adjusted Metrics

Adjusted profitability remained a bright spot, with Q4 adjusted EBITDA up 13.7% to an unchanged margin of 24.3%, showing that growth is not diluting earnings quality. Normalized earnings from operations rose 13.3% to $60.4 million, adjusted net earnings reached $38.5 million and adjusted diluted EPS came in at $0.90.

High-ROI China Execution and Consumer Conversion

Management highlighted China as a high-return investment story, citing performance marketing that is translating awareness into sales. Brand awareness to trial conversion jumped 57%, and trial to regular-buyer conversion climbed 81%, allowing Jamieson to grow roughly four times faster than the broader vitamins, minerals and supplements market.

Strong Cash Position and Shareholder Returns

The company ended the year with $126.6 million in cash and available facilities, giving it ample flexibility despite near-term working-capital pressures. Jamieson returned capital aggressively, repurchasing about 1.2 million shares for $37.9 million and paying roughly $37.2 million in dividends, with a further $0.23-per-share dividend declared.

Operational Improvements and Innovation Momentum

Operationally, Jamieson completed the rollout of a new SAP system across headquarters and three manufacturing sites, a key step for scaling efficiently. Innovation continued to focus on high-demand need states like immunity, sleep, stress and energy, with a “global-to-local” model speeding successful products into new markets and retailers.

Strategic Partners Revenue Decline

Strategic Partner revenues were a weak spot, declining 4.4% in Q4, or about $1.9 million, as volumes softened and customer onboarding was delayed amid trade and tariff uncertainty. Segment gross profit fell 2.4%, underscoring some sensitivity to external policy and logistics factors.

Higher SG&A and One-Time Due Diligence Costs

SG&A jumped 20% in Q4, or $9.8 million, as Jamieson leaned into performance marketing, especially in China, and built out global infrastructure and variable compensation. The quarter also absorbed $2.7 million of legal and professional expenses linked to due diligence on an acquisition that ultimately failed to meet return thresholds.

Reported Operating Income Nearly Flat After Investments

Despite strong growth in revenue and gross profit, reported earnings from operations were essentially flat in Q4, slipping about 0.02% as spending ramped up. Management emphasized that on a normalized basis operating income still climbed, framing the gap as largely tied to deliberate brand-building and one-off deal costs.

Working Capital Build and Cash from Operations Pressure

Cash from operations fell to $31.9 million from $37.8 million a year earlier, but performance before working capital actually improved, reflecting underlying earnings strength. The drag came from an $18.8 million working-capital increase driven by higher inventory to cushion tariff risks and port congestion, a trend management expects to continue into 2026.

M&A Pipeline Caution and Deal Costs

Management signaled a cautious approach to acquisitions, noting that a recent potential deal was dropped after not meeting internal criteria even after due diligence spending. The pipeline remains focused on scaled, U.S.-based brands around $100 million or more in revenue, but timing and certainty of transactions remain unclear.

Early-Stage GLP-1-Related Opportunity and Category Sensitivities

Executives flagged GLP-1 companion products as an emerging but still modest category, with early uptake encouraging yet not material to overall results. They also cited seasonal swings, including a December immunity spike, while framing GLP-1 as a possible longer-term tailwind whose impact and timing are still difficult to forecast.

Forward-Looking Guidance and Growth Outlook

For 2026, Jamieson guided consolidated revenue to $895 million–$935 million, implying 9%–14% growth, with Jamieson Brands expected to grow 9%–13% and China projected to surge another 20%–30%. Adjusted EBITDA is forecast at $174 million–$181 million and adjusted EPS at $2.08–$2.21, alongside solid cash generation before working capital and planned investments in inventory and roughly $20 million of capex.

Overall, Jamieson Wellness’ call painted a picture of a growth company investing heavily but selectively in its brands, capabilities and balance sheet resilience. For investors, the message was that strong international and China-driven expansion, rising margins and disciplined capital returns outweigh near-term noise in partner revenue, working capital and deal-related costs.